Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renzhu Changle Granule is a Traditional Chinese Medicine (TCM) botanical formulation developed for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). It is specifically indicated for patients presenting with the TCM syndrome of liver stagnation and spleen deficiency. The drug has been evaluated in Phase II clinical trials in China, involving institutions such as the Beijing Chinese Medicine Hospital and Hong Kong Baptist University, with PuraPharm (Nanning) Corporation serving as a developer and manufacturer. The formulation is designed to alleviate gastrointestinal symptoms by harmonizing the liver and spleen, a traditional approach to managing functional bowel disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renzhu Changle Granule.